Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCYM9Q)

Drug Name
XT-150 Drug Info
Indication
Disease Entry ICD 11 Status REF
Knee osteoarthritis FA01 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMCYM9Q

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-10 (IL10) DTT IL10 5.87 4.853 5.092 5.629
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Knee osteoarthritis
ICD Disease Classification FA01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-10 (IL10) DTT IL10 1.07E-02 0.08 0.56
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04124042) A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Xalud Therapeutics